Skip to main content

Table 1 Overview of studies

From: Development and external validation of predictive models for prevalent and recurrent atrial fibrillation: a protocol for the analysis of the CATCH ME combined dataset

Study (location) N Study details Population Age (years) Sex (% males) Major endpoints FU (lost to FU)
Flec SL – AFNET 3 [18, 51], (Germany) 635 Controlled trial comparing short- and long-term flecainide therapy after cardioversion in patients with persistent AF AF 18–89 66% Recurrent AF. MACE events centrally adjudicated and available. 6 months
AFCT (Netherlands) 388 Observational: Retrospective, case-control SR, AF 23–74 68% MACE 2–3 years
BBC-AF (United Kingdom) 1632 Registry SR, AF 20–97 60% MACCE. Recurrent AF is captured clinically 2 years
FUTURE (Spain) 198 Registry SR, AF 22–60 85% Retrospective follow-up (clinical AF recurrence/incidence) 4–5 years
RACE IV (Netherlands) 1370 Controlled trial of “holistic” AF management and usual care, recently detected AF AF 19–89 66% MACE, recurrent AF, AF progression 2–3 years
MULTIAF (Netherlands) 70 Observational: Prospective AF 33–83 77% Recurrence of persistent AF 6 months
READ-POAF (Netherlands) 79 Observational SR 42–84 73% Incident AF, MACCE 3 years
Tissue bank 246 Combined tissue bank AF 20–85 70% Tissue characteristics, no specific follow-up Variable
AFLMU (Germany) 3573 Ongoing registry of AF patients from a large arrhythmia clinic AF 16–93 69% Recurrent AF following intervention (Follow-up available for part of the cohort) ongoing.
Median 1 year FU
KORA (Germany) 4279 Population-based survey including digital ECG, biosamples and detailed characterization SR 25–74 49% Incidence of death, stroke, and myocardial infarction Ongoing since enrolment
GIRAFA [52] (Spain) 210 Patients with lone AF AF 18–70 70% Retrospective follow-up Mean 9 years (AF patients)
PVIBCN [53] (Spain) 1088 Cohort of patients undergoing AF ablation AF 19–79 74% Ongoing, systematic follow-up for AF recurrence. 1–2 years
  1. FU Follow-up, SR Sinus rhythm, AF Atrial fibrillation, MACE Major adverse cardiovascular events, MACCE Major adverse cardiovascular and cerebrovascular events